UNSPSC 51123117: Pilsicainide

This classification denotes an antiarrhythmic agent with the molecular formula C17H24N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) AV0X7V6CSE, chemically known as 1h-pyrrolizine-7a(5h)-acetamide, n-(2,6-dimethylphenyl)tetrahydro- but more generally known as pilsicainide, which bears US NIH Compound Identifier 4820. European Medicines Agency schedules Pilsicainide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09834MIG. The term PILSICAINIDE is an International Non-Proprietary Name.

UNSPSC 51123117 Pilsicainide is a Commodity code representing a single pharmaceutical product line. State and local governments procure pilsicainide and related antiarrhythmic medications through emergency medical services departments, health agencies, and cooperative purchasing organizations that supply hospitals, fire rescue services, and public health systems. The work involves sourcing branded or generic formulations, managing expiration dates and shelf life, ensuring FDA compliance and Good Manufacturing Practice certification, coordinating logistics and delivery timelines, and meeting regulatory documentation requirements including Safety Data Sheets and chain-of-custody tracking. Issuing bodies include city purchasing departments (acting on behalf of fire rescue and EMS), state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating state and local jurisdictions.

Recent activity shows three distinct procurement approaches across Florida, Texas, and the multistate cooperative region. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications including multiple antiarrhythmic agents for Tampa Fire Rescue, with a response deadline of April 8, 2026 and an estimated contract value of $40,000 over one year plus optional renewals; the solicitation included a 5 percent SLBE bid discount and required firms to arrange for expired-material replacement before the nine-month expiration threshold. The Texas Health and Human Services Commission posted an RFI in April 2026 exploring direct-to-manufacturer prescription fulfillment strategies outside traditional pharmacy benefit manager and group purchasing organization channels, signaling state interest in alternative contracting models for pharmaceutical supply. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 (due March 26, 2026) establishing multiple-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon, requiring vendors to maintain relationships with three authorized wholesalers and achieve 75 percent evaluation weight on price competitiveness. The code shows active procurement across municipal, state, and cooperative purchasing channels, with emphasis on compliance documentation, wholesaler integration, and competitive pricing.